Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The Trump administration has called for 30 days of measures, including staying at least six feet away from other people, that have upended American life as most people stay isolated at home, shuttering schools and closing businesses through at least the end of April, with some states continuing certain closures through May and June. Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, said such steps must continue but that there are hopeful signs they are working. "If in fact we are successful, it makes sense to at least plan what a re-entry into normality would look like. That doesn't mean we're going to do it right now, but it means we need to be prepared to ease into that," Fauci, a member of the White House coronavirus task force, told Fox News in an interview. Fauci and other public health experts have said the strict measures are needed to control the fast-spreading and potentially fatal disease that has already led to about 400,000 confirmed COVID-19 U.S. cases and nearly 13,000 deaths, even as the shutdowns have roiled the U.S. economy. Dr. Deborah Birx, another task force member, said isolation measures must continue for now or else the country could risk a repeated spike despite the allure of warmer spring weather. "What's really important is that people don't turn these early signs of hope into releasing from the 30 days to stop the spread. It's really critical," she told NBC News' "Today" program. "If people start going out again and socially interacting, we could see a really acute second wave." Asked if 30-day distancing practices would be enough or that steps might have to continue longer, she said officials were looking at each area of the country differently as they weigh the data. "Clearly, there are metro areas that are struggling," Birx said.
[A]: U.S. planning ways to 'ease' back to normal if virus efforts work: Fauci.

[Q]: The story mentioned that the cost of this drug treatment was several thousand dollars a month and that this was higher than the costs of other treatments. It would have been better to provide a more concrete estimate of costs (several thousand does this mean 2,3 or 6 thousand?). The story might have included some information about additional costs that would be encountered with the comparison treatment such as the cost of intraveneous infusions, testing to evaluate side-effects, and other connected costs. The story did a good job reporting the data comparing patient survival with Iressa as compared to individuals treated with IV chemotherapy. The story skimmed over the side effects; reducing the frequency of bothersome or life threatening side effects would seem to be an advantage. The story mentioned quality of life factors that appear to be better with Iressa but did not quantify the benefit observed. Borderline satisfactory. The story listed the common side effects of the treatment though it failed to indicate the frequency with which these were seen. In addition, rather than than merely listing these, the story could have included some information about the severity of the side effects (i.e. bothersome vs. fatal). The story provided information about the size of the study conducted, the nature of the patients that were enrolled, and that the drug company that markets the drug funded the study. The study was designed as a non-inferiority survival trial to compare this medication with docotaxel, a chemotherapy treatment often used in individuals who have lung cancer and have had platinum based treatment but who are experiencing a return of their cancer. (While the story did provide information about the survival outcomes, it also included information comparing side effects.) The story ended with a comment from one of the interviewed clinicians about quality of life being better with Iressa. The story should have been clearer about the predetermined endpoint of the study (longevity) and should not have ended with less data driven information. The story did not engage in overt disease mongering. However the headline does not hint that the trial is not about first-line cancer treatment, rather just patients who have been treated previously with a platinum-based chemotherapy. The story included quotes from two individuals identified as not being connected with the study reported upon but with relevant expertise. The story provided information about two treatment options for individuals who have recurrence of a previously treated lung cancer. It did not provide information about the natural history of not undergoing additional treatment for this condition which is necessary for evaluating the relative merit of the two treatments discussed. The story did not mention radiation and surgery which are both options for some limited cancers. The story mentions that the medication Iressa (gefitinib) is sold in the United States but that its availability in Europe is limited. The story presented the use of Iressa as a treatment of individuals with lung cancer who had previously been treated with a platinum-based regimen as though it was a novel application. However this drug was approved by the FDA in 2003 for this purpose. While the results of study reported on are interesting, the story did not provide the reader with a realistic picture of about the novelty of this product. Does not appear to rely on a press release.
[A]: Pill as good as chemo on lung cancer, but costlier

[Q]: Almost three years after he received bone marrow stem cells from a donor with a rare genetic mutation that resists HIV infection - and more than 18 months after he came off antiretroviral drugs - highly sensitive tests still show no trace of the man's previous HIV infection. "There is no virus there that we can measure. We can't detect anything," said Ravindra Gupta, a professor and HIV biologist who co-led a team of doctors treating the man. AIDS experts said the case is a proof of the concept that scientists will one day be able to end AIDS, and marks a "critical moment" in the search for an HIV cure, but does not mean that cure has already been found. Gupta described his patient as "functionally cured" and "in remission", but cautioned: "It's too early to say he's cured." The man is being called "the London patient", in part because his case is similar to the first known case of a functional cure of HIV - in an American man, Timothy Brown, who became known as the Berlin patient when he underwent similar treatment in Germany in 2007 which also cleared his HIV. Brown, who had been living in Berlin, has since moved to the United States and, according to HIV experts, is still HIV-free. Some 37 million people worldwide are currently infected with HIV and the AIDS pandemic has killed about 35 million people worldwide since it began in the 1980s. Scientific research into the complex virus has in recent years led to the development of drug combinations that can keep it at bay in most patients. Gupta, now at Cambridge University, treated the London patient when he was working at University College London. The man had contracted HIV in 2003, Gupta said, and in 2012 was also diagnosed with a type of blood cancer called Hodgkin's Lymphoma. In 2016, when he was very sick with cancer, doctors decided to seek a transplant match for him. "This was really his last chance of survival," Gupta told Reuters. The donor - who was unrelated - had a genetic mutation known as 'CCR5 delta 32', which confers resistance to HIV. The transplant went relatively smoothly, Gupta said, but there were some side effects, including the patient suffering a period of "graft-versus-host" disease - a condition in which donor immune cells attack the recipient's immune cells. Most experts say it is inconceivable such treatments could be a way of curing all patients. The procedure is expensive, complex and risky. To do this in others, exact match donors would have to be found in the tiny proportion of people most of them of northern European descent who have the CCR5 mutation that makes them resistant to the virus. "Although this is not a viable large-scale strategy for a cure, it does represent a critical moment," said Anton Pozniak, president of the International AIDS Society. "The hope is that this will eventually lead to a safe, cost-effective and easy strategy...using gene technology or antibody techniques." Specialists said it is also not yet clear whether the CCR5 resistance is the only key - or whether the graft-versus-host disease may have been just as important. Both the Berlin and London patients had this complication, which may have played a role in the loss of HIV-infected cells, Gupta said. His team plans to use these findings to explore potential new HIV treatment strategies. "We need to understand if we could knock out this (CCR5) receptor in people with HIV, which may be possible with gene therapy," he said. The London patient, whose case was set to be reported in the journal Nature and presented at a medical conference in Seattle on Tuesday, has asked his medical team not to reveal his name, age, nationality or other details.
[A]:
London HIV patient becomes world's second AIDS cure hope.